Sellas Life Sciences is trading 4.12% up at $13.77 after announcing on September 2, 2026, that three abstracts evaluating SLS009 in pancreatic cancer models were accepted for presentation at the 2026 AACR Conference on Pancreatic Cancer.
- The research involves patient-derived KRAS-mutant organoids.
- It explores CDK9 combinations with BET- and KRAS-directed therapies.
- No numerical efficacy data or explicit stock-market attribution was provided.